{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:08:39Z","timestamp":1787656119556,"version":"build-2736575974"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R41CA239989"],"award-info":[{"award-number":["R41CA239989"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R44CA239989"],"award-info":[{"award-number":["R44CA239989"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-15-011-01-CDD"],"award-info":[{"award-number":["RSG-15-011-01-CDD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11095-025-03917-0","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T21:27:08Z","timestamp":1756157228000},"page":"2353-2368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Physiological Considerations and Delivery Strategies for Targeting Tumors Through Intraperitoneal Delivery"],"prefix":"10.1007","volume":"42","author":[{"given":"Md Jobair Hossen","family":"Jony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheyda","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyed Majid","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mittal","family":"Darji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1961-8156","authenticated-orcid":false,"given":"Xiuling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"3917_CR1","doi-asserted-by":"publisher","unstructured":"Arslan OE. Peritoneal Organ-Anatomical and Physiological Considerations. In: Shegokar R, editor. Exploring Drug Delivery to the Peritoneum [Internet]. Cham: Springer International Publishing; 2023 [cited 2025 May 26]. p. 1\u201336. https:\/\/doi.org\/10.1007\/978-3-031-31694-4_1.","DOI":"10.1007\/978-3-031-31694-4_1"},{"issue":"1","key":"3917_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0016-5085(98)70646-8","volume":"114","author":"JC Hall","year":"1998","unstructured":"Hall JC, Heel KA, Papadimitriou JM, Platell C. The pathobiology of peritonitis. Gastroenterology. 1998;114(1):185\u201396.","journal-title":"Gastroenterology"},{"key":"3917_CR3","unstructured":"Kalra A, Wehrle CJ, Tuma F. Anatomy, Abdomen and Pelvis, Peritoneum. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 May 26]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534788\/."},{"issue":"2","key":"3917_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1681\/ASN.V22122","volume":"2","author":"MF Flessner","year":"1991","unstructured":"Flessner MF. Peritoneal transport physiology: insights from basic research. J Am Soc Nephrol. 1991;2(2):122.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"3917_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/bjs.1800830804","volume":"83","author":"KA Heel","year":"1996","unstructured":"Heel KA, Hall JC. Peritoneal defences and peritoneum-associated lymphoid tissue. Br J Surg. 1996;83(8):1031\u20136.","journal-title":"Br J Surg"},{"issue":"7","key":"3917_CR6","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1007\/s00261-015-0429-5","volume":"40","author":"HK Pannu","year":"2015","unstructured":"Pannu HK, Oliphant M. The subperitoneal space and peritoneal cavity: basic concepts. Abdom Imaging. 2015;40(7):2710\u201322.","journal-title":"Abdom Imaging"},{"issue":"373","key":"3917_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jconrel.2024.07.017","volume":"1","author":"MT Perell\u00f3-Trias","year":"2024","unstructured":"Perell\u00f3-Trias MT, Serrano-Mu\u00f1oz AJ, Rodr\u00edguez-Fern\u00e1ndez A, Segura-Sampedro JJ, Ramis JM, Monjo M. Intraperitoneal drug delivery systems for peritoneal carcinomatosis: Bridging the gap between research and clinical implementation. J Controlled Release. 2024;1(373):70\u201392.","journal-title":"J Controlled Release"},{"issue":"1","key":"3917_CR8","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1\u201311.","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"3917_CR9","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/annonc\/mdm518","volume":"19","author":"AMC Swart","year":"2008","unstructured":"Swart AMC, Burdett S, Ledermann J, Mook P, Parmar MKB. Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. Ann Oncol. 2008;19(4):688\u201395.","journal-title":"Ann Oncol"},{"issue":"5","key":"3917_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","volume":"4","author":"M Markman","year":"2003","unstructured":"Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4(5):277\u201383.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3917_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijpharm.2009.08.034","volume":"383","author":"N Mirahmadi","year":"2010","unstructured":"Mirahmadi N, Babaei MH, Vali AM, Dadashzadeh S. Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice. Int J Pharm. 2010;383(1):7\u201313.","journal-title":"Int J Pharm"},{"issue":"5","key":"3917_CR12","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3390\/ijms19051373","volume":"19","author":"CH Chen","year":"2018","unstructured":"Chen CH, Kuo CY, Chen SH, Mao SH, Chang CY, Shalumon KT, et al. Thermosensitive Injectable Hydrogel for Simultaneous Intraperitoneal Delivery of Doxorubicin and Prevention of Peritoneal Adhesion. Int J Mol Sci. 2018;19(5):1373.","journal-title":"Int J Mol Sci"},{"issue":"29","key":"3917_CR13","doi-asserted-by":"publisher","first-page":"18963","DOI":"10.1021\/acsnano.4c02312","volume":"18","author":"S Liang","year":"2024","unstructured":"Liang S, Xiao L, Chen T, Roa P, Cocco E, Peng Z, et al. Injectable Nanocomposite Hydrogels Improve Intraperitoneal Co-delivery of Chemotherapeutics and Immune Checkpoint Inhibitors for Enhanced Peritoneal Metastasis Therapy. ACS Nano. 2024;18(29):18963\u201379.","journal-title":"ACS Nano"},{"issue":"4","key":"3917_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/BF00047468","volume":"6","author":"RK Jain","year":"1987","unstructured":"Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6(4):559\u201393.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"3917_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mvr.2007.05.003","volume":"74","author":"D Fukumura","year":"2007","unstructured":"Fukumura D, Jain RK. Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74(2):72\u201384.","journal-title":"Microvasc Res"},{"issue":"1","key":"3917_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0169-409X(00)00131-9","volume":"46","author":"RK Jain","year":"2001","unstructured":"Jain RK. Delivery of molecular and cellular medicine to solid tumors1. Adv Drug Deliv Rev. 2001;46(1):149\u201368.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"3917_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","volume":"89","author":"RL Dedrick","year":"1997","unstructured":"Dedrick RL, Flessner MF. Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface Exposure. JNCI J Natl Cancer Inst. 1997;89(7):480\u20137.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"10","key":"3917_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin CH, Rubin K, Pietras K, \u00d6stman A. High interstitial fluid pressure \u2014 an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806\u201313.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"3917_CR19","first-page":"3380","volume":"49","author":"G Los","year":"1989","unstructured":"Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989;49(12):3380\u20134.","journal-title":"Cancer Res"},{"issue":"8","key":"3917_CR20","first-page":"3209","volume":"39","author":"RF Ozols","year":"1979","unstructured":"Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of Adriamycin and Tissue Penetration in Murine Ovarian Cancer. Cancer Res. 1979;39(8):3209\u201314.","journal-title":"Cancer Res"},{"issue":"2","key":"3917_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1445-5994.2009.02112.x","volume":"41","author":"SJ Dawson","year":"2011","unstructured":"Dawson SJ, Hicks RJ, Johnston V, Allen D, Jobling T, Quinn M, et al. Intraperitoneal distribution imaging in ovarian cancer patients. Intern Med J. 2011;41(2):167\u201371.","journal-title":"Intern Med J"},{"issue":"11","key":"3917_CR22","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3390\/jpm12111799","volume":"12","author":"DW Hwang","year":"2022","unstructured":"Hwang DW, Lee EJ, Chung JY, Lee EJ, Kim D, Oh SH, et al. Optimal Nozzle Position and Patient\u2019s Posture to Enhance Drug Delivery into the Peritoneum during Rotational Intraperitoneal Pressurized Aerosol Chemotherapy in a Swine Model. J Pers Med. 2022;12(11):1799.","journal-title":"J Pers Med"},{"issue":"5","key":"3917_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s11095-009-0031-z","volume":"27","author":"G Bajaj","year":"2010","unstructured":"Bajaj G, Yeo Y. Drug Delivery Systems for Intraperitoneal Therapy. Pharm Res. 2010;27(5):735\u20138.","journal-title":"Pharm Res"},{"issue":"4","key":"3917_CR24","first-page":"1237","volume":"8","author":"H Gelderblom","year":"2002","unstructured":"Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, et al. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8(4):1237\u201341.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"3917_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4254\/wjh.v5.i5.251","volume":"5","author":"CM Moore","year":"2013","unstructured":"Moore CM, Van Thiel DH. Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol. 2013;5(5):251\u201363.","journal-title":"World J Hepatol"},{"issue":"1","key":"3917_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/j.1552-4604.1984.tb01812.x","volume":"24","author":"R Sampliner","year":"1984","unstructured":"Sampliner R, Perrier D, Powell R, Finley P. Influence of Ascites on Tobramycin Pharmacokinetics. J Clin Pharmacol. 1984;24(1):43\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"3917_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1471-0528.2011.03179.x","volume":"119","author":"C Helm","year":"2012","unstructured":"Helm C. Ports and complications for intraperitoneal chemotherapy delivery. BJOG Int J Obstet Gynaecol. 2012;119(2):150\u20139.","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"28","key":"3917_CR28","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1200\/JCO.2006.06.0376","volume":"24","author":"M Gore","year":"2006","unstructured":"Gore M, du Bois A, Vergote I. Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental. J Clin Oncol. 2006;24(28):4528\u201330.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3917_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1006\/gyno.2000.6108","volume":"81","author":"S Makhija","year":"2001","unstructured":"Makhija S, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L, et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol. 2001;81(1):77\u201381.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"3917_CR30","first-page":"508","volume":"22","author":"ALM Oei","year":"2007","unstructured":"Oei ALM, Massuger LFAG, Oyen WJG. Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer. Cancer Biother Radiopharm. 2007;22(4):508\u201314.","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"3917_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ygyno.2009.01.016","volume":"113","author":"SM Kehoe","year":"2009","unstructured":"Kehoe SM, Williams NL, Yakubu R, Levine DA, Chi DS, Sabbatini PJ, et al. Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. Gynecol Oncol. 2009;113(2):228\u201332.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"3917_CR32","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/BF02234701","volume":"44","author":"MC Parker","year":"2001","unstructured":"Parker MC, Ellis H, Moran BJ, Thompson JN, Wilson MS, Menzies D, et al. Postoperative adhesions: Ten-year follow-up of 12,584 patients undergoing lower abdominal surgery. Dis Colon Rectum. 2001;44(6):822\u20139.","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"3917_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1006\/gyno.2000.5979","volume":"79","author":"N Sakuragi","year":"2000","unstructured":"Sakuragi N, Nakajima A, Nomura E, Noro N, Yamada H, Yamamoto R, et al. Complications Relating to Intraperitoneal Administration of Cisplatin or Carboplatin for Ovarian Carcinoma. Gynecol Oncol. 2000;79(3):420\u20133.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3917_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1515\/med-2016-0021","volume":"11","author":"A Rocca","year":"2016","unstructured":"Rocca A, Aprea G, Surfaro G, Amato M, Giuliani A, Paccone M, et al. Prevention and treatment of peritoneal adhesions in patients affected by vascular diseases following surgery: a review of the literature. Open Med. 2016;11(1):106\u201314.","journal-title":"Open Med"},{"issue":"1","key":"3917_CR35","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ygyno.2012.05.002","volume":"127","author":"D Herr","year":"2012","unstructured":"Herr D, Sallmann A, Bekes I, Konrad R, Holzheu I, Kreienberg R, et al. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol. 2012;127(1):210\u20136.","journal-title":"Gynecol Oncol"},{"issue":"21","key":"3917_CR36","doi-asserted-by":"publisher","first-page":"11105","DOI":"10.1074\/jbc.M116.724690","volume":"291","author":"K Udwan","year":"2016","unstructured":"Udwan K, Brideau G, Fila M, Edwards A, Vogt B, Doucet A. Oxidative Stress and Nuclear Factor \u03baB (NF-\u03baB) Increase Peritoneal Filtration and Contribute to Ascites Formation in Nephrotic Syndrome *. J Biol Chem. 2016;291(21):11105\u201313.","journal-title":"J Biol Chem"},{"issue":"2","key":"3917_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/0022-4804(87)90109-0","volume":"42","author":"RN Garrison","year":"1987","unstructured":"Garrison RN, Galloway RH, Heuser LS. Mechanisms of malignant ascites production. J Surg Res. 1987;42(2):126\u201332.","journal-title":"J Surg Res"},{"issue":"3","key":"3917_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jnci\/56.3.547","volume":"56","author":"J Fastaia","year":"1976","unstructured":"Fastaia J, Dumont AE. Pathogenesis of Ascites in Mice With Peritoneal Carcinomatosis2. JNCI J Natl Cancer Inst. 1976;56(3):547\u201350.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"3917_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11095-020-02818-8","volume":"37","author":"S Alavi","year":"2020","unstructured":"Alavi S, Haeri A, Mahlooji I, Dadashzadeh S. Tuning the Physicochemical Characteristics of Particle-Based Carriers for Intraperitoneal Local Chemotherapy. Pharm Res. 2020;37(6):119.","journal-title":"Pharm Res"},{"key":"3917_CR40","doi-asserted-by":"publisher","unstructured":"Miao L, Huang L. Exploring the Tumor Microenvironment with Nanoparticles. In: Mirkin CA, Meade TJ, Petrosko SH, Stegh AH, editors. Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer [Internet]. Cham: Springer International Publishing; 2015 [cited 2025 May 14]. p. 193\u2013226. https:\/\/doi.org\/10.1007\/978-3-319-16555-4_9.","DOI":"10.1007\/978-3-319-16555-4_9"},{"issue":"2","key":"3917_CR41","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jconrel.2010.08.026","volume":"148","author":"S Dadashzadeh","year":"2010","unstructured":"Dadashzadeh S, Mirahmadi N, Babaei MH, Vali AM. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge. J Controlled Release. 2010;148(2):177\u201386.","journal-title":"J Controlled Release"},{"issue":"50","key":"3917_CR42","doi-asserted-by":"publisher","first-page":"31588","DOI":"10.1039\/C7RA04349J","volume":"7","author":"Y Gao","year":"2017","unstructured":"Gao Y, Zhu X, Zhang Y, Chen X, Wang L, Feng W, et al. In vivo biodistribution and passive accumulation of upconversion nanoparticles in colorectal cancer models via intraperitoneal injection. RSC Adv. 2017;7(50):31588\u201396.","journal-title":"RSC Adv"},{"issue":"328","key":"3917_CR43","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.jconrel.2020.11.003","volume":"10","author":"D Hargrove","year":"2020","unstructured":"Hargrove D, Liang B, Kashfi-Sadabad R, Joshi GN, Gonzalez-Fajardo L, Glass S, et al. Tumor-mesoporous silica nanoparticle interactions following intraperitoneal delivery for targeting peritoneal metastasis. J Controlled Release. 2020;10(328):846\u201358.","journal-title":"J Controlled Release"},{"issue":"4","key":"3917_CR44","doi-asserted-by":"publisher","first-page":"1900058","DOI":"10.1002\/ppsc.201900058","volume":"36","author":"R Kashfi-Sadabad","year":"2019","unstructured":"Kashfi-Sadabad R, Gonzalez-Fajardo L, Hargrove D, Ahmadi B, Munteanu D, Shahbazmohamadi S, et al. Engineering Multifunctional Gold Decorated Dendritic Mesoporous Silica\/Tantalum Oxide Nanoparticles for Intraperitoneal Tumor-Specific Delivery. Part Part Syst Charact. 2019;36(4):1900058.","journal-title":"Part Part Syst Charact"},{"issue":"7","key":"3917_CR45","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/j.1349-7006.2010.01587.x","volume":"101","author":"M Matsui","year":"2010","unstructured":"Matsui M, Shimizu Y, Kodera Y, Kondo E, Ikehara Y, Nakanishi H. Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer. Cancer Sci. 2010;101(7):1670\u20137.","journal-title":"Cancer Sci"},{"issue":"17","key":"3917_CR46","doi-asserted-by":"publisher","first-page":"8740","DOI":"10.1158\/0008-5472.CAN-06-0470","volume":"66","author":"Y Ikehara","year":"2006","unstructured":"Ikehara Y, Niwa T, Biao L, Ikehara SK, Ohashi N, Kobayashi T, et al. A Carbohydrate Recognition-Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle. Cancer Res. 2006;66(17):8740\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"3917_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/17425247.2024.2439462","volume":"22","author":"Z Cai","year":"2025","unstructured":"Cai Z, Liu B, Cai Q, Gou J, Tang X. Advances in microsphere-based therapies for peritoneal carcinomatosis: challenges, innovations, and future prospects. Expert Opin Drug Deliv. 2025;22(1):31\u201346.","journal-title":"Expert Opin Drug Deliv."},{"issue":"7","key":"3917_CR48","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/j.nano.2016.04.013","volume":"12","author":"Q Fu","year":"2016","unstructured":"Fu Q, Hargrove D, Lu X. Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery. Nanomedicine Nanotechnol Biol Med. 2016;12(7):1951\u20139.","journal-title":"Nanomedicine Nanotechnol Biol Med"},{"issue":"9","key":"3917_CR49","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s11095-012-0765-x","volume":"29","author":"L De Smet","year":"2012","unstructured":"De Smet L, Colin P, Ceelen W, Bracke M, Van Bocxlaer J, Remon JP, et al. Development of a Nanocrystalline Paclitaxel Formulation for Hipec Treatment. Pharm Res. 2012;29(9):2398\u2013406.","journal-title":"Pharm Res"},{"issue":"5","key":"3917_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1211\/0022357023303","volume":"56","author":"K Yokogawa","year":"2004","unstructured":"Yokogawa K, Jin M, Furui N, Yamazaki M, Yoshihara H, Nomura M, et al. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles. J Pharm Pharmacol. 2004;56(5):629\u201334.","journal-title":"J Pharm Pharmacol"},{"issue":"915","key":"3917_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174512","volume":"15","author":"D Vyas","year":"2022","unstructured":"Vyas D, Patel M, Wairkar S. Strategies for active tumor targeting-an update. Eur J Pharmacol. 2022;15(915): 174512.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"3917_CR52","doi-asserted-by":"publisher","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","volume":"288","author":"MF Flessner","year":"2005","unstructured":"Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol-Ren Physiol. 2005;288(3):F433\u201342.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"3917_CR53","doi-asserted-by":"publisher","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. In: Sugarbaker PH, editor. Peritoneal Carcinomatosis: Principles of Management [Internet]. Boston, MA: Springer US; 1996 [cited 2025 Jun 11]. p. 53\u201363. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_4.","DOI":"10.1007\/978-1-4613-1247-5_4"},{"issue":"1","key":"3917_CR54","doi-asserted-by":"publisher","first-page":"18496","DOI":"10.3402\/nano.v3i0.18496","volume":"3","author":"GL Zwicke","year":"2012","unstructured":"Zwicke GL, Ali Mansoori G, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012;3(1):18496.","journal-title":"Nano Rev"},{"issue":"Pt B","key":"3917_CR55","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jconrel.2015.09.007","volume":"220","author":"SS Desale","year":"2015","unstructured":"Desale SS, Soni KS, Romanova S, Cohen SM, Bronich TK. Targeted delivery of platinum-taxane combination therapy in ovarian cancer. J Control Release Off J Control Release Soc. 2015;220(Pt B):651\u20139.","journal-title":"J Control Release Off J Control Release Soc"},{"issue":"1","key":"3917_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-009-1132-4","volume":"66","author":"A Gabizon","year":"2010","unstructured":"Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, et al. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol. 2010;66(1):43\u201352.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1A","key":"3917_CR57","first-page":"343","volume":"25","author":"XQ Pan","year":"2005","unstructured":"Pan XQ, Lee RJ. In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model. Anticancer Res. 2005;25(1A):343\u20136.","journal-title":"Anticancer Res"},{"issue":"7","key":"3917_CR58","first-page":"739","volume":"14","author":"A Chaudhury","year":"2012","unstructured":"Chaudhury A, Das S, Bunte RM, Chiu GN. Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. Int J Nanomedicine. 2012;14(7):739\u201351.","journal-title":"Int J Nanomedicine"},{"issue":"33","key":"3917_CR59","doi-asserted-by":"publisher","first-page":"8548","DOI":"10.1016\/j.biomaterials.2011.07.067","volume":"32","author":"ME Werner","year":"2011","unstructured":"Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, et al. Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials. 2011;32(33):8548\u201354.","journal-title":"Biomaterials"},{"issue":"22","key":"3917_CR60","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/sj.gt.3301833","volume":"9","author":"JA Reddy","year":"2002","unstructured":"Reddy JA, Abburi C, Hofland H, Howard SJ, Vlahov I, Wils P, et al. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 2002;9(22):1542\u201350.","journal-title":"Gene Ther"},{"issue":"1","key":"3917_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13048-016-0230-2","volume":"9","author":"H Zhang","year":"2016","unstructured":"Zhang H, Li J, Hu Y, Shen M, Shi X, Zhang G. Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancer. J Ovarian Res. 2016;9(1):19.","journal-title":"J Ovarian Res"},{"issue":"7","key":"3917_CR62","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1021\/acsbiomaterials.9b00006","volume":"5","author":"R Kotcherlakota","year":"2019","unstructured":"Kotcherlakota R, Vydiam K, Jeyalakshmi Srinivasan D, Mukherjee S, Roy A, Kuncha M, et al. Restoration of p53 Function in Ovarian Cancer Mediated by Gold Nanoparticle-Based EGFR Targeted Gene Delivery System. ACS Biomater Sci Eng. 2019;5(7):3631\u201344.","journal-title":"ACS Biomater Sci Eng"},{"issue":"23","key":"3917_CR63","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1158\/1078-0432.CCR-10-2055","volume":"16","author":"ES Glazer","year":"2010","unstructured":"Glazer ES, Zhu C, Massey KL, Thompson CS, Kaluarachchi WD, Hamir AN, et al. Noninvasive Radiofrequency Field Destruction of Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles. Clin Cancer Res. 2010;16(23):5712\u201321.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3917_CR64","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3109\/08982100903544185","volume":"20","author":"S Sofou","year":"2010","unstructured":"Sofou S, Enmon R, Palm S, Kappel B, Zanzonico P, McDevitt MR, et al. Large anti-HER2\/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. J Liposome Res. 2010;20(4):330\u201340.","journal-title":"J Liposome Res"},{"issue":"9","key":"3917_CR65","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3109\/1061186X.2011.589436","volume":"19","author":"A Fondell","year":"2011","unstructured":"Fondell A, Edwards K, Unga J, Kullberg E, Park JW, Gedda L. In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an 125I-labelled DNA-intercalator. J Drug Target. 2011;19(9):846\u201355.","journal-title":"J Drug Target"},{"issue":"34","key":"3917_CR66","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1039\/C7TB01587A","volume":"5","author":"R Kotcherlakota","year":"2017","unstructured":"Kotcherlakota R, Srinivasan DJ, Mukherjee S, Haroon MM, Dar GH, Venkatraman U, et al. Engineered fusion protein-loaded gold nanocarriers for targeted co-delivery of doxorubicin and erbB2-siRNA in human epidermal growth factor receptor-2+ ovarian cancer. J Mater Chem B. 2017;5(34):7082\u201398.","journal-title":"J Mater Chem B"},{"issue":"6","key":"3917_CR67","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/cas.14909","volume":"112","author":"E Kondo","year":"2021","unstructured":"Kondo E, Iioka H, Saito K. Tumor-homing peptide and its utility for advanced cancer medicine. Cancer Sci. 2021;112(6):2118\u201325.","journal-title":"Cancer Sci"},{"issue":"104","key":"3917_CR68","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.biomaterials.2016.07.023","volume":"1","author":"L Sim\u00f3n-Gracia","year":"2016","unstructured":"Sim\u00f3n-Gracia L, Hunt H, Scodeller P, Gaitzsch J, Kotamraju VR, Sugahara KN, et al. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes. Biomaterials. 2016;1(104):247\u201357.","journal-title":"Biomaterials"},{"issue":"166","key":"3917_CR69","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.biomaterials.2018.02.052","volume":"1","author":"E Wonder","year":"2018","unstructured":"Wonder E, Sim\u00f3n-Gracia L, Scodeller P, Majzoub RN, Kotamraju VR, Ewert KK, et al. Competition of charge-mediated and specific binding by peptide-tagged cationic liposome\u2013DNA nanoparticles in vitro and in vivo. Biomaterials. 2018;1(166):52\u201363.","journal-title":"Biomaterials"},{"issue":"260","key":"3917_CR70","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jconrel.2017.06.005","volume":"28","author":"H Hunt","year":"2017","unstructured":"Hunt H, Sim\u00f3n-Gracia L, Tobi A, Kotamraju VR, Sharma S, Nigul M, et al. Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles. J Controlled Release. 2017;28(260):142\u201353.","journal-title":"J Controlled Release"},{"issue":"6","key":"3917_CR71","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.7150\/thno.18125","volume":"7","author":"N Gao","year":"2017","unstructured":"Gao N, Bozeman EN, Qian W, Wang L, Chen H, Lipowska M, et al. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery. Theranostics. 2017;7(6):1689\u2013704.","journal-title":"Theranostics"},{"issue":"29","key":"3917_CR72","doi-asserted-by":"publisher","first-page":"26861","DOI":"10.18632\/oncotarget.4766","volume":"6","author":"CC Wu","year":"2015","unstructured":"Wu CC, Yang YC, Hsu YT, Wu TC, Hung CF, Huang JT, et al. Nanoparticle-induced intraperitoneal hyperthermia and targeted photoablation in treating ovarian cancer. Oncotarget. 2015;6(29):26861\u201375.","journal-title":"Oncotarget"},{"issue":"1","key":"3917_CR73","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1021\/mp900242f","volume":"7","author":"SD Li","year":"2010","unstructured":"Li SD, Howell SB. CD44-Targeted Microparticles for Delivery of Cisplatin to Peritoneal Metastases. Mol Pharm. 2010;7(1):280\u201390.","journal-title":"Mol Pharm"},{"issue":"19","key":"3917_CR74","doi-asserted-by":"publisher","first-page":"2100287","DOI":"10.1002\/smll.202100287","volume":"17","author":"MS Singh","year":"2021","unstructured":"Singh MS, Ramishetti S, Landesman-Milo D, Goldsmith M, Chatterjee S, Palakuri R, et al. Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer. Small. 2021;17(19):2100287.","journal-title":"Small"},{"issue":"26","key":"3917_CR75","doi-asserted-by":"publisher","first-page":"22776","DOI":"10.18632\/oncotarget.4309","volume":"6","author":"M Nowacki","year":"2015","unstructured":"Nowacki M, Wisniewski M, Werengowska-Ciecwierz K, Roszek K, Czarnecka J, \u0141akomska I, et al. Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis. Oncotarget. 2015;6(26):22776\u201398.","journal-title":"Oncotarget"},{"issue":"1","key":"3917_CR76","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/1471-2407-13-400","volume":"13","author":"SL Macura","year":"2013","unstructured":"Macura SL, Steinbacher JL, MacPherson MB, Lathrop MJ, Sayan M, Hillegass JM, et al. Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts. BMC Cancer. 2013;13(1):400.","journal-title":"BMC Cancer"},{"issue":"6","key":"3917_CR77","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1111\/cas.13605","volume":"109","author":"J Li","year":"2018","unstructured":"Li J, Yao S, Wang K, Lu Z, Su X, Li L, et al. Hypocrellin B-loaded, folate-conjugated polymeric micelle for intraperitoneal targeting of ovarian cancer in vitro and in vivo. Cancer Sci. 2018;109(6):1958\u201369.","journal-title":"Cancer Sci"},{"issue":"391","key":"3917_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2016.12.032","volume":"10","author":"T Luo","year":"2017","unstructured":"Luo T, Sun J, Zhu S, He J, Hao L, Xiao L, et al. Ultrasound-mediated destruction of oxygen and paclitaxel loaded dual-targeting microbubbles for intraperitoneal treatment of ovarian cancer xenografts. Cancer Lett. 2017;10(391):1\u201311.","journal-title":"Cancer Lett"},{"key":"3917_CR79","unstructured":"Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. [Internet]. [cited 2025 May 14]. Available from: https:\/\/sites.ualberta.ca\/~csps\/JPPS7(4)SpecialIssue\/S.McQuarrie\/nanopharmaceuticals.htm."},{"issue":"1","key":"3917_CR80","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1021\/mp400523h","volume":"11","author":"C Pu","year":"2014","unstructured":"Pu C, Chang S, Sun J, Zhu S, Liu H, Zhu Y, et al. Ultrasound-Mediated Destruction of LHRHa Targeted and Paclitaxel Loaded Lipid Microbubbles for the Treatment of Intraperitoneal Ovarian Cancer Xenografts. Mol Pharm. 2014;11(1):49\u201358.","journal-title":"Mol Pharm"},{"issue":"9","key":"3917_CR81","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.3390\/nano11092222","volume":"11","author":"M Gisbert-Garzar\u00e1n","year":"2021","unstructured":"Gisbert-Garzar\u00e1n M, Vallet-Reg\u00ed M. Redox-Responsive Mesoporous Silica Nanoparticles for Cancer Treatment: Recent Updates. Nanomaterials. 2021;11(9):2222.","journal-title":"Nanomaterials"},{"issue":"8","key":"3917_CR82","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1039\/c3nr00114h","volume":"5","author":"AH Colby","year":"2013","unstructured":"Colby AH, Colson YL, Grinstaff MW. Microscopy and tunable resistive pulse sensing characterization of the swelling of pH-responsive, polymeric expansile nanoparticles. Nanoscale. 2013;5(8):3496\u2013504.","journal-title":"Nanoscale"},{"issue":"7","key":"3917_CR83","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1021\/ja807416t","volume":"131","author":"AP Griset","year":"2009","unstructured":"Griset AP, Walpole J, Liu R, Gaffey A, Colson YL, Grinstaff MW. Expansile Nanoparticles: Synthesis, Characterization, and in Vivo Efficacy of an Acid-Responsive Polymeric Drug Delivery System. J Am Chem Soc. 2009;131(7):2469\u201371.","journal-title":"J Am Chem Soc"},{"issue":"9","key":"3917_CR84","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2217\/nnm-2015-0023","volume":"11","author":"VL Herrera","year":"2016","unstructured":"Herrera VL, Colby AH, Tan GA, Moran AM, O\u2019Brien MJ, Colson YL, et al. Evaluation of Expansile Nanoparticle Tumor Localization and Efficacy in a Cancer Stem Cell-Derived Model of Pancreatic Peritoneal Carcinomatosis. Nanomed. 2016;11(9):1001\u201315.","journal-title":"Nanomed."},{"issue":"10","key":"3917_CR85","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.addr.2008.03.009","volume":"60","author":"J Wu","year":"2008","unstructured":"Wu J, Nyborg WL. Ultrasound, cavitation bubbles and their interaction with cells. Adv Drug Deliv Rev. 2008;60(10):1103\u201316.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3917_CR86","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/pharmaceutics14020324","volume":"14","author":"M Rezaeian","year":"2022","unstructured":"Rezaeian M, Soltani M, Naseri Karimvand A, Raahemifar K. Mathematical Modeling of Targeted Drug Delivery Using Magnetic Nanoparticles during Intraperitoneal Chemotherapy. Pharmaceutics. 2022;14(2):324.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3917_CR87","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2967\/jnumed.112.106609","volume":"54","author":"AJD Pasqua","year":"2013","unstructured":"Pasqua AJD, Yuan H, Chung Y, Kim JK, Huckle JE, Li C, et al. Neutron-Activatable Holmium-Containing Mesoporous Silica Nanoparticles as a Potential Radionuclide Therapeutic Agent for Ovarian Cancer. J Nucl Med. 2013;54(1):111\u20136.","journal-title":"J Nucl Med"},{"issue":"669","key":"3917_CR88","doi-asserted-by":"publisher","first-page":"125071","DOI":"10.1016\/j.ijpharm.2024.125071","volume":"25","author":"D Hargrove","year":"2025","unstructured":"Hargrove D, Ranjbar S, Darji M, Nam S, Dawson RJ, Katugampola S, et al. Tumor specific delivery and radiation-enhanced tumor penetration of mesoporous silica nanoparticles for effective radionuclide therapy of ovarian peritoneal metastasis. Int J Pharm. 2025;25(669):125071.","journal-title":"Int J Pharm"},{"issue":"5","key":"3917_CR89","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/01.sla.0000251519.49405.55","volume":"245","author":"Y Yeo","year":"2007","unstructured":"Yeo Y, Ito T, Bellas E, Highley CB, Marini R, Kohane DS. In Situ Cross-linkable Hyaluronan Hydrogels Containing Polymeric Nanoparticles for Preventing Postsurgical Adhesions. Ann Surg. 2007;245(5):819.","journal-title":"Ann Surg"},{"issue":"20","key":"3917_CR90","doi-asserted-by":"publisher","first-page":"7759","DOI":"10.1039\/c2ra20612a","volume":"2","author":"Y Xie","year":"2012","unstructured":"Xie Y, Long Q, Wu Q, Shi S, Dai M, Liu Y, et al. Improving therapeutic effect in ovarian peritoneal carcinomatosis with honokiol nanoparticles in a thermosensitive hydrogel composite. RSC Adv. 2012;2(20):7759\u201371.","journal-title":"RSC Adv"},{"issue":"1","key":"3917_CR91","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ijpharm.2010.03.033","volume":"392","author":"JY Lee","year":"2010","unstructured":"Lee JY, Kim KS, Kang YM, Kim ES, Hwang SJ, Lee HB, et al. In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth. Int J Pharm. 2010;392(1):51\u20136.","journal-title":"Int J Pharm"},{"issue":"1","key":"3917_CR92","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/1471-2407-10-402","volume":"10","author":"Y Wang","year":"2010","unstructured":"Wang Y, Gong C, Yang L, Wu Q, Shi S, Shi H, et al. 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice. BMC Cancer. 2010;10(1):402.","journal-title":"BMC Cancer"},{"issue":"6","key":"3917_CR93","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.nano.2011.10.010","volume":"8","author":"C Gong","year":"2012","unstructured":"Gong C, Yang B, Qian Z, Zhao X, Wu Q, Qi X, et al. Improving intraperitoneal chemotherapeutic effect and preventing postsurgical adhesions simultaneously with biodegradable micelles. Nanomedicine Nanotechnol Biol Med. 2012;8(6):963\u201373.","journal-title":"Nanomedicine Nanotechnol Biol Med"},{"issue":"1","key":"3917_CR94","doi-asserted-by":"publisher","first-page":"720858","DOI":"10.1155\/2013\/720858","volume":"2013","author":"L De Smet","year":"2013","unstructured":"De Smet L, Ceelen W, Remon JP, Vervaet C. Optimization of Drug Delivery Systems for Intraperitoneal Therapy to Extend the Residence Time of the Chemotherapeutic Agent. Sci World J. 2013;2013(1):720858.","journal-title":"Sci World J"},{"issue":"152","key":"3917_CR95","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.ijbiomac.2020.02.326","volume":"1","author":"J Luo","year":"2020","unstructured":"Luo J, Wu Z, Lu Y, Xiong K, Wen Q, Zhao L, et al. Intraperitoneal administration of biocompatible hyaluronic acid hydrogel containing multi-chemotherapeutic agents for treatment of colorectal peritoneal carcinomatosis. Int J Biol Macromol. 2020;1(152):718\u201326.","journal-title":"Int J Biol Macromol"},{"issue":"235","key":"3917_CR96","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jconrel.2016.05.056","volume":"10","author":"B Sun","year":"2016","unstructured":"Sun B, Taha MS, Ramsey B, Torregrosa-Allen S, Elzey BD, Yeo Y. Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals. J Controlled Release. 2016;10(235):91\u20138.","journal-title":"J Controlled Release"},{"issue":"3","key":"3917_CR97","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jconrel.2011.11.025","volume":"158","author":"P Zahedi","year":"2012","unstructured":"Zahedi P, Stewart J, De Souza R, Piquette-Miller M, Allen C. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. J Controlled Release. 2012;158(3):379\u201385.","journal-title":"J Controlled Release"},{"issue":"4","key":"3917_CR98","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.mehy.2015.07.001","volume":"85","author":"CB Tempfer","year":"2015","unstructured":"Tempfer CB. Pressurized intraperitoneal aerosol chemotherapy as an innovative approach to treat peritoneal carcinomatosis. Med Hypotheses. 2015;85(4):480\u20134.","journal-title":"Med Hypotheses"},{"issue":"1","key":"3917_CR99","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/cancers12010034","volume":"12","author":"G Nadiradze","year":"2020","unstructured":"Nadiradze G, Horvath P, Sautkin Y, Archid R, Weinreich FJ, K\u00f6nigsrainer A, et al. Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Cancers. 2020;12(1):34.","journal-title":"Cancers"},{"key":"3917_CR100","unstructured":"PIPAC: Pressurized IntraPeritoneal Aerosol Chemotherapy \u2013 Cancer under Pressure [Internet]. De Gruyter; 2014 [cited 2025 Jun 4]. Available from: https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/9783110366617\/html."},{"issue":"2","key":"3917_CR101","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, M\u00fcrdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy. Ann Surg Oncol. 2014;21(2):553\u20139.","journal-title":"Ann Surg Oncol"},{"key":"3917_CR102","doi-asserted-by":"crossref","unstructured":"Eveno C, Jouvin I, Pocard M. PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study. Pleura Peritoneum [Internet]. 2018 Jun 1 [cited 2025 Jun 4];3(2). Available from: https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0116\/html?utm_source=chatgpt.com.","DOI":"10.1515\/pp-2018-0116"},{"issue":"10","key":"3917_CR103","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.ejso.2015.06.001","volume":"41","author":"K Odendahl","year":"2015","unstructured":"Odendahl K, Solass W, Demtr\u00f6der C, Giger-Pabst U, Zieren J, Tempfer C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41(10):1379\u201385.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"3917_CR104","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368\u201377.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3917_CR105","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/00001813-199607000-00016","volume":"7","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Stuart OA, Chang D, Sugarbaker PH. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs. 1996;7(5):596.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"3917_CR106","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","volume":"244","author":"P Esquis","year":"2006","unstructured":"Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, et al. High Intra-abdominal Pressure Enhances the Penetration and Antitumor Effect of Intraperitoneal Cisplatin on Experimental Peritoneal Carcinomatosis. Ann Surg. 2006;244(1):106.","journal-title":"Ann Surg"},{"key":"3917_CR107","doi-asserted-by":"crossref","unstructured":"Breusa S, Zilio S, Catania G, Bakrin N, Kryza D, Lollo G. Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer. Front Oncol [Internet]. 2023 May 23 [cited 2025 Apr 8];13. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2023.1125868\/full.","DOI":"10.3389\/fonc.2023.1125868"},{"issue":"1","key":"3917_CR108","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s12885-021-07955-w","volume":"21","author":"M Mimouni","year":"2021","unstructured":"Mimouni M, Richard C, Adenot P, Letheule M, Tarrade A, Sandra O, et al. Pressurized intra-peritoneal aerosol chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution patterns but leads to deeper penetration depth of doxorubicin in a sheep model. BMC Cancer. 2021;21(1):461.","journal-title":"BMC Cancer"},{"issue":"1","key":"3917_CR109","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1038\/s41598-022-10369-8","volume":"12","author":"M Rahimi-Gorji","year":"2022","unstructured":"Rahimi-Gorji M, Debbaut C, Ghorbaniasl G, Cosyns S, Willaert W, Ceelen W. Optimization of intraperitoneal aerosolized drug delivery using computational fluid dynamics (CFD) modeling. Sci Rep. 2022;12(1):6305.","journal-title":"Sci Rep"},{"key":"3917_CR110","unstructured":"Rahimi-Gorji M, Ghorbaniasl G, Cosyns S, Willaert W, Ceelen W. Effect of fluid flow rate and droplet size on spatial aerosol distribution during pressurized intraperiational aerosol chemotherapy (PIPAC). 26th Congr Eur Soc Biomech ESB 2021 [Internet]. 2021 [cited 2025 Apr 8]; Available from: http:\/\/hdl.handle.net\/1854\/LU-8714242."},{"issue":"4","key":"3917_CR111","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1245\/s10434-015-4954-9","volume":"23","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Diaz-Carballo D, F\u00f6rster E, Zieren J, Giger-Pabst U. Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Ann Surg Oncol. 2016;23(4):1220\u20134.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"3917_CR112","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","volume":"142","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Kern AJP, Osma A, Kabakci B, Diaz-Carballo D, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016;142(11):2275\u201380.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"3917_CR113","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/jso.25418","volume":"119","author":"JP De Andrade","year":"2019","unstructured":"De Andrade JP, Warner SG, Fong Y. Treatment of metastatic colorectal cancer: innovations in surgical techniques. J Surg Oncol. 2019;119(5):653\u20139.","journal-title":"J Surg Oncol"},{"issue":"1","key":"3917_CR114","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1080\/10717544.2021.1937382","volume":"28","author":"SJ Park","year":"2021","unstructured":"Park SJ, Lee EJ, Lee HS, Kim J, Park S, Ham J, et al. Development of rotational intraperitoneal pressurized aerosol chemotherapy to enhance drug delivery into the peritoneum. Drug Deliv. 2021;28(1):1179\u201387.","journal-title":"Drug Deliv."},{"issue":"9","key":"3917_CR115","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.21873\/anticanres.11008","volume":"36","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Falkenstein TA, Diaz-Carballo D, F\u00f6rster E, Osma A, et al. Evaluating the Effect of Micropump\u00a9 Position, Internal Pressure and Doxorubicin Dosage on Efficacy of Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. Anticancer Res. 2016;36(9):4595\u2013600.","journal-title":"Anticancer Res"},{"issue":"11","key":"3917_CR116","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.ijmultiphaseflow.2004.07.006","volume":"30","author":"SS Yoon","year":"2004","unstructured":"Yoon SS, Hewson JC, DesJardin PE, Glaze DJ, Black AR, Skaggs RR. Numerical modeling and experimental measurements of a high speed solid-cone water spray for use in fire suppression applications. Int J Multiph Flow. 2004;30(11):1369\u201388.","journal-title":"Int J Multiph Flow"},{"issue":"11","key":"3917_CR117","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.21873\/anticanres.15362","volume":"41","author":"J Piao","year":"2021","unstructured":"Piao J, Park SJ, Lee H, Kim J, Park S, Lee N, et al. Ideal Nozzle Position During Pressurized Intraperitoneal Aerosol Chemotherapy in an Ex Vivo Model. Anticancer Res. 2021;41(11):5489\u201398.","journal-title":"Anticancer Res"},{"issue":"10","key":"3917_CR118","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1109\/TMI.2002.806270","volume":"21","author":"KA Salem","year":"2002","unstructured":"Salem KA, Szymanski-Exner A, Lazebnik RS, Breen MS, Gao J, Wilson DL. X-ray computed tomography methods for in vivo evaluation of local drug release systems. IEEE Trans Med Imaging. 2002;21(10):1310\u20136.","journal-title":"IEEE Trans Med Imaging"},{"issue":"12","key":"3917_CR119","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1002\/adfm.201302312","volume":"24","author":"XD Zhang","year":"2014","unstructured":"Zhang XD, Chen J, Min Y, Park GB, Shen X, Song SS, et al. Metabolizable Bi2Se3 Nanoplates: Biodistribution, Toxicity, and Uses for Cancer Radiation Therapy and Imaging. Adv Funct Mater. 2014;24(12):1718\u201329.","journal-title":"Adv Funct Mater"},{"issue":"11","key":"3917_CR120","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1021\/mp500173s","volume":"11","author":"R Chakravarty","year":"2014","unstructured":"Chakravarty R, Hong H, Cai W. Positron Emission Tomography Image-Guided Drug Delivery: Current Status and Future Perspectives. Mol Pharm. 2014;11(11):3777\u201397.","journal-title":"Mol Pharm"},{"key":"3917_CR121","doi-asserted-by":"crossref","unstructured":"Van Der Veldt A, Smit E, Lammertsma AA. Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [11C]docetaxel. Front Oncol [Internet]. 2013 Aug 13 [cited 2025 Aug 5];3. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2013.00208\/full.","DOI":"10.3389\/fonc.2013.00208"},{"issue":"5","key":"3917_CR122","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3390\/cancers13050963","volume":"13","author":"\u00c1 Bella","year":"2021","unstructured":"Bella \u00c1, Di Trani CA, Fern\u00e1ndez-Sendin M, Arrizabalaga L, Cirella A, Teijeira \u00c1, et al. Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications. Cancers. 2021;13(5):963.","journal-title":"Cancers"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03917-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03917-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03917-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:02:26Z","timestamp":1768932146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03917-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":122,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3917"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03917-0","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Xiuling Lu is an inventor on intellectual property licensed to Nami Therapeutics Corp for developing silica nanoparticle-based radiopharmaceuticals. Dr. Xiuling Lu owns equity. It is important to note that the analysis and interpretation in this study were without any influence from the potential financial gains. The authors affirm\u00a0that the conclusions drawn and the information provided in this paper are based on scientific evidence.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}